Citadel Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.28M | Sell |
128,800
-80,200
| -38% | -$4.68M | ﹤0.01% | 3743 |
|
|
2025
Q4 | $12.4M | Sell |
209,000
-3,200
| -2% | -$174K | ﹤0.01% | 2969 |
|
|
2025
Q3 | $11.5M | Buy |
212,200
+18,200
| +9% | +$1.04M | ﹤0.01% | 3071 |
|
|
2025
Q2 | $10.7M | Buy |
194,000
+39,600
| +26% | +$2.33M | ﹤0.01% | 2938 |
|
|
2025
Q1 | $10.9M | Buy |
154,400
+59,000
| +62% | +$3.97M | ﹤0.01% | 2736 |
|
|
2024
Q4 | $6.27M | Sell |
95,400
-41,400
| -30% | -$2.77M | ﹤0.01% | 3608 |
|
|
2024
Q3 | $9.62M | Sell |
136,800
-49,300
| -26% | -$4.12M | ﹤0.01% | 2951 |
|
|
2024
Q2 | $15.3M | Buy |
186,100
+125,200
| +206% | +$10.4M | ﹤0.01% | 2287 |
|
|
2024
Q1 | $5.32M | Sell |
60,900
-32,800
| -35% | -$2.94M | ﹤0.01% | 3866 |
|
|
2023
Q4 | $9.03M | Buy |
93,700
+33,000
| +54% | +$2.92M | ﹤0.01% | 2986 |
|
|
2023
Q3 | $5.37M | Sell |
60,700
-28,700
| -32% | -$2.55M | ﹤0.01% | 3540 |
|
|
2023
Q2 | $7.75M | Sell |
89,400
-39,800
| -31% | -$3.75M | ﹤0.01% | 3014 |
|
|
2023
Q1 | $12.6M | Sell |
129,200
-4,600
| -3% | -$477K | ﹤0.01% | 2501 |
|
|
2022
Q4 | $13.8M | Buy |
133,800
+16,700
| +14% | +$1.57M | ﹤0.01% | 2394 |
|
|
2022
Q3 | $9.93M | Buy |
117,100
+10,300
| +10% | +$917K | ﹤0.01% | 2774 |
|
|
2022
Q2 | $8.85M | Sell |
106,800
-5,800
| -5% | -$462K | ﹤0.01% | 2856 |
|
|
2022
Q1 | $8.68M | Sell |
112,600
-34,400
| -23% | -$2.88M | ﹤0.01% | 3190 |
|
|
2021
Q4 | $13M | Sell |
147,000
-83,200
| -36% | -$6.87M | ﹤0.01% | 2638 |
|
|
2021
Q3 | $17.8M | Buy |
230,200
+70,300
| +44% | +$5.55M | ﹤0.01% | 2181 |
|
|
2021
Q2 | $13.3M | Buy |
159,900
+23,700
| +17% | +$1.88M | ﹤0.01% | 2638 |
|
|
2021
Q1 | $10.3M | Sell |
136,200
-96,700
| -42% | -$7.9M | ﹤0.01% | 2923 |
|
|
2020
Q4 | $20.4M | Buy |
232,900
+67,200
| +41% | +$5.33M | 0.01% | 1777 |
|
|
2020
Q3 | $12.6M | Buy |
165,700
+10,000
| +6% | +$1.01M | ﹤0.01% | 2016 |
|
|
2020
Q2 | $19.2M | Buy |
155,700
+73,400
| +89% | +$7.3M | 0.01% | 1536 |
|
|
2020
Q1 | $6.95M | Sell |
82,300
-49,500
| -38% | -$4.27M | ﹤0.01% | 2290 |
|
|
2019
Q4 | $11.1M | Buy |
131,800
+77,200
| +141% | +$5.83M | ﹤0.01% | 2082 |
|
|
2019
Q3 | $3.68M | Sell |
54,600
-24,800
| -31% | -$1.91M | ﹤0.01% | 3545 |
|
|
2019
Q2 | $6.8M | Sell |
79,400
-24,600
| -24% | -$2.1M | ﹤0.01% | 2670 |
|
|
2019
Q1 | $9.24M | Buy |
104,000
+24,300
| +30% | +$2.25M | ﹤0.01% | 2172 |
|
|
2018
Q4 | $6.79M | Buy |
79,700
+14,000
| +21% | +$1.33M | ﹤0.01% | 2372 |
|
|
2018
Q3 | $6.37M | Buy |
65,700
+7,500
| +13% | +$749K | ﹤0.01% | 2669 |
|
|
2018
Q2 | $5.48M | Buy |
58,200
+17,800
| +44% | +$1.56M | ﹤0.01% | 2639 |
|
|
2018
Q1 | $3.27M | Buy |
40,400
+6,000
| +17% | +$515K | ﹤0.01% | 3019 |
|
|
2017
Q4 | $3.07M | Buy |
34,400
+3,900
| +13% | +$339K | ﹤0.01% | 3066 |
|
|
2017
Q3 | $2.84M | Buy |
30,500
+2,400
| +9% | +$212K | ﹤0.01% | 2991 |
|
|
2017
Q2 | $2.55M | Sell |
28,100
-2,600
| -8% | -$237K | ﹤0.01% | 2858 |
|
|
2017
Q1 | $2.69M | Buy |
30,700
+900
| +3% | +$80.1K | ﹤0.01% | 2717 |
|
|
2016
Q4 | $2.47M | Sell |
29,800
-5,300
| -15% | -$456K | ﹤0.01% | 2709 |
|
|
2016
Q3 | $3.25M | Buy |
35,100
+9,600
| +38% | +$904K | ﹤0.01% | 2418 |
|
|
2016
Q2 | $1.98M | Sell |
25,500
-11,500
| -31% | -$978K | ﹤0.01% | 2757 |
|
|
2016
Q1 | $3.05M | Buy |
37,000
+1,500
| +4% | +$122K | ﹤0.01% | 2224 |
|
|
2015
Q4 | $3.72M | Buy |
35,500
+9,900
| +39% | +$1.03M | ﹤0.01% | 2090 |
|
|
2015
Q3 | $2.7M | Sell |
25,600
-24,700
| -49% | -$3.3M | ﹤0.01% | 2589 |
|
|
2015
Q2 | $6.88M | Sell |
50,300
-25,100
| -33% | -$3.11M | 0.01% | 1754 |
|
|
2015
Q1 | $9.4M | Buy |
75,400
+8,600
| +13% | +$911K | 0.01% | 1513 |
|
|
2014
Q4 | $6.04M | Buy |
66,800
+8,000
| +14% | +$665K | 0.01% | 1807 |
|
|
2014
Q3 | $4.24M | Sell |
58,800
-87,900
| -60% | -$5.78M | ﹤0.01% | 2134 |
|
|
2014
Q2 | $9.13M | Buy |
146,700
+109,100
| +290% | +$6.59M | 0.01% | 1337 |
|
|
2014
Q1 | $2.56M | Sell |
37,600
-11,300
| -23% | -$833K | ﹤0.01% | 2401 |
|
|
2013
Q4 | $3.44M | Buy |
48,900
+24,900
| +104% | +$1.69M | ﹤0.01% | 2020 |
|
|
2013
Q3 | $1.73M | Sell |
24,000
-9,600
| -29% | -$638K | ﹤0.01% | 2552 |
|
|
2013
Q2 | $1.88M | Buy |
+33,600
| New | +$2.09M | ﹤0.01% | 2551 |
|
Other funds holding BMRN
VCM
VPM
Citadel Advisors's BMRN Position: Q1 2026 in Review
Citadel Advisors increased its BioMarin Pharmaceuticals (BMRN) stake by 231% in Q1 2026, buying an estimated $184M and bringing the position to 4,512,634 shares worth $255M. The position accounts for 0.04% of the portfolio, ranked #355.
Citadel Advisors first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $263M in Q4 2020. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Citadel Advisors held 4,512,634 shares of BioMarin Pharmaceuticals worth $255M as of Q1 2026.
- Citadel Advisors bought 3,147,943 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $184M.
- BioMarin Pharmaceuticals made up 0.04% of Citadel Advisors's portfolio in Q1 2026, its #355 holding.
- Citadel Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citadel Advisors's BioMarin Pharmaceuticals position peaked at $263M in Q4 2020.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.